Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 56

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 56
---
 stock equivalents in lieu thereof (the Company sold 15,000 shares of its common stock and 112,551 pre-funded warrants);
and (ii) common warrants to purchase up to 127,551 shares of common stock (the “Warrants”), at a combined public offering
price of $39.20 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase
agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company
and each investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received
net proceeds of approximately $4.2 million, which is net of offering costs and fees of $839,004. During the three months ended March 31,
2025, 15,000 shares of common stock were purchased upon the closing of the Offering and 91,214 shares were issued in connection with the
exercise of pre-funded warrants, totaling 106,214 shares of its common stock issued of the aggregate amount of 127,551 Common Stock shares
sold. During the three months ended June 30, 2025, 10,550 shares were issued in connection with the exercise of pre-funded warrants. As
of September 30, 2025, 10,787 pre-funded warrants remain exercisable.

The Warrants have an exercise
price of $39.20 per share, are immediately exercisable upon stockholder approval and have a term of exercise equal to five years following
the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment
in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

In connection with the Offering,
on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Alliance
Global Partners (“A.G.P.”), as the exclusive placement agent in connection with the Offering (the “Placement Agent”).
Pursuant to a side letter between the Placement Agent and JonesTrading Institutional Services LLC (“Jones”), dated February
3, 2025, Jones agreed to be a financial advisor for the Offering. In connection with the services provided by Jones, the Placement Agent
and Jones agreed that the Placement Agent will receive an aggregate fee equal to 6% of the gross proceeds received in the Offering and